title: Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  Relatively few studies have focused on T4N2 (stage IIIB) locally advanced non-small cell lung cancer (NSCLC). In this study, we tried to identify prognostic factors for patients with clinical stage T4N2 NSCLC.
  
  
  METHODS
  We retrospectively identified 223 patients, of which 168 met the inclusion criteria. Patients treated with curative intent using concurrent chemoradiotherapy (CRT) with or without adjuvant chemotherapy, or concurrent CRT after induction chemotherapy, were included in this study. Relevant patient, treatment, and disease factors were evaluated for their prognostic significance in both univariate and multivariate analyses using the Cox proportional hazards model.
  
  
  RESULTS
  The median progression-free survival (PFS) was 13 months (95% confidence interval [CI], 10.6-15.4). The median overall survival (OS) was 20 months (95% CI, 16.8-23.1), and 71, 40.3 and 28.2% of the patients survived for 1, 2 and 3 years after diagnosis, respectively. Multivariate analysis showed Eastern Cooperative Oncology Group (ECOG) performance status (PS) was independent predictor of PFS (hazard ratio [HR], 0.24; 95% CI, 0.13-0.43; p=0.001), and OS [HR, 0.48; 95% CI, 0.26-0.87; p=0.015). Absence of multifocal T4 tumors was also associated with a significantly longer OS (HR, 046; 95% CI, 0.31-0.7; p=0.001). There was no statistically significant difference in OS and PFS between treatment modalities.
  
  
  CONCLUSIONS
  PFS and OS were significantly shorter in patients with poor ECOG PS. OS was also significantly shorter in patients with multifocal T4 tumors. There were no differences between the two therapeutic approaches with respect to outcome.
authors.affiliation: Erzurum Research and Education Hospital, Medical Oncology Department, Erzurum, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Arslan
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.forename: Timur
authors.initials: T
authors.lastname: Koca
authors.forename: Didem
authors.initials: D
authors.lastname: Tastekin
authors.forename: Arda
authors.initials: A
authors.lastname: Kaymak Cerkesli
authors.forename: Hamit
authors.initials: H
authors.lastname: Basaran
authors.forename: Seyda
authors.initials: S
authors.lastname: Gunduz
authors.forename: Ali
authors.initials: A
authors.lastname: Murat Tatli
authors.forename: Sema
authors.initials: S
authors.lastname: Sezgin Goksu
authors.forename: Mukremin
authors.initials: M
authors.lastname: Uysal
authors.forename: Aysegul
authors.initials: A
authors.lastname: Kargi
authors.forename: Bulent
authors.initials: B
authors.lastname: Kargi
authors.forename: Lokman
authors.initials: L
authors.lastname: Koral
authors.forename: Cumhur
authors.initials: C
authors.lastname: Ibrahim Bassorgun
authors.forename: Dilek
authors.initials: D
authors.lastname: Unal
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.forename: Hasan
authors.initials: H
authors.lastname: Senol Coskun
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozdogan
authors.forename: Hakan
authors.initials: H
authors.lastname: Bozcuk
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies